Related Experiment Video

Updated: Oct 7, 2025

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.0K

The Effect of Curative Treatment on Hyperglycemia in Patients With Cushing Syndrome

Justine Herndon1, Ravinder Jeet Kaur2, Mark Romportl1

  • 1Division of Endocrinology, Diabetes and Nutrition, Mayo Clinic, Rochester, Minnesota 55905, USA.

Journal of the Endocrine Society
|January 6, 2022
PubMed

Insights

Curative procedures significantly improve hyperglycemia in Cushing syndrome (CS) patients. Two-thirds experienced resolution or improvement, highlighting the need for monitoring during recovery.

Area of Science:

  • Endocrinology
  • Metabolic Disorders
  • Surgical Outcomes

Background:

  • Hyperglycemia is a frequent complication of Cushing syndrome (CS).
  • Effective management of hyperglycemia in CS is crucial for patient outcomes.

Purpose of the Study:

  • To evaluate the impact of curative procedures on hyperglycemia and its treatment in patients with Cushing syndrome.
  • To identify factors associated with hyperglycemia improvement post-treatment.

Main Methods:

  • Retrospective longitudinal cohort study of adult patients with endogenous CS and hyperglycemia (2000-2019).
  • Assessed changes in glycated hemoglobin A1c (HbA1c), hyperglycemia therapy intensity, and overall improvement.
  • Analyzed outcomes based on CS subtype and hypercortisolism severity.

Main Results:

  • Following curative procedures, 21% of patients achieved hyperglycemia resolution, and 47% showed improvement.
  • HbA1c levels decreased by 0.84% (P < .001), and insulin dosage reduced by 30 units (P < .001).
  • Severe hypercortisolism and non-adrenal CS subtypes were associated with better hyperglycemia improvement.

Conclusions:

  • Curative procedures offer significant benefits for hyperglycemia in a majority of Cushing syndrome patients.
  • Close monitoring and adjustment of hyperglycemia therapy are essential during the recovery phase after CS treatment.
Abstract

Keywords:
HbA1cdiabetes mellitushypercortisolismimprovementoutcomesurgery

More Related Videos

Author Spotlight: Investigating the Blood Glucose Homeostasis in Murine Brain Using a Cost-Effective Hyperglycemic And Hypoglycemic Clamp Technique07:35

Author Spotlight: Investigating the Blood Glucose Homeostasis in Murine Brain Using a Cost-Effective Hyperglycemic And Hypoglycemic Clamp Technique

Published on: January 26, 2024

1.7K
Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain08:32

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain

Published on: January 4, 2018

10.5K

Related Concept Videos

Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
370
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
433
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
334
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
296
Overview of Carbohydrate Metabolism01:19

Overview of Carbohydrate Metabolism

Carbohydrate metabolism is a fundamental biochemical process that ensures a constant supply of energy to living cells. The most important carbohydrate is glucose, which can be broken down via glycolysis to enter into the Krebs cycle and eventually lead to the production of ATP through oxidative phosphorylation.
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
2.1K
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
382